Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gómez-Abad, C.
Right arrow Articles by Serratosa, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gómez-Abad, C.
Right arrow Articles by Serratosa, J. M.
Related Collections
Right arrow Metabolic disease (inherited)
Right arrow Myoclonus
Right arrow All Genetics
NEUROLOGY 2005;64:982-986
© 2005 American Academy of Neurology

Lafora disease due to EPM2B mutations

A clinical and genetic study

C. Gómez-Abad, BSc, P. Gómez-Garre, PhD, E. Gutiérrez-Delicado, MD, S. Saygi, MD, R. Michelucci, MD, C. A. Tassinari, MD, S. Rodríguez de Córdoba, PhD and J. M. Serratosa, MD, PhD

From the Neurology Service (Drs. Serratosa, Gómez-Garre, and Gutiérrez-Delicado, C. Gómez-Abad), Fundación Jiménez Díaz, Madrid, Spain; Hacettepe University Hospital (Dr. Saygi), Ankara, Turkey; Unità Operativa di Neurologia (Drs. Michelucci and Tassinari), Ospedale Bellaria C.A. Pizzardi, Bologna, Italy; and Departamento de Inmunología (Dr. Rodríguez de Córdoba), Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.

Address correspondence and reprint requests to Dr. José Serratosa, Servicio de Neurología, Fundación Jiménez Díaz, Avda Reyes Católicos 2, 28040, Madrid, Spain; e-mail: serratosa{at}telefonica.net

Objective: To study EPM2B gene mutations and genotype-phenotype correlations in patients with Lafora disease.

Methods: The authors performed a clinical and mutational analysis of 25 patients, from 23 families, diagnosed with Lafora disease who had not shown mutations in the EPM2A gene.

Results: The authors identified 18 mutations in EPM2B, including 12 novel mutations: 4 nonsense mutations (R265X, C26X, W219X, and E67X), a 6-base pair (bp) microdeletion resulting in a two amino acid deletion (V294_K295del), a 4-bp insertion resulting in a frameshift mutation (S339fs12), and 6 missense mutations (D308A, I198N, C68Y, E67Q, P264H, and D233A). In our data set of 77 families with Lafora disease, 54 (70.1%) tested probands have mutations in EPM2A, 21 (27.3%) in EPM2B, and 2 (2.6%) have no mutations in either gene. The course of the disease was longer in patients with EPM2B mutations vs patients with EPM2A mutations.

Conclusions: Genetic allelic heterogeneity is present in Lafora disease associated with mutations in EPM2B. Patients with mutations in EPM2A and EPM2B express similar clinical manifestation, although patients with EPM2B-associated Lafora disease seem to have a slightly milder clinical course. The lack of mutations in EPM2A and EPM2B in two families could be because of the presence of mutations in noncoding, nontested regions or the existence of an additional gene associated with Lafora disease.

Supported by the Asociación Lafora España, the Fondo de Investigaciones Sanitarias (FIS PI020536, FIS 603/054), and Comisión Interministerial de Ciencia y Tecnología (SAF 99–0013-CO2–02). This study is based on work supported by the Fundación Conchita Rábago de Jiménez Díaz under fellowships awarded to C.G-A.

Received August 30, 2004. Accepted in final form November 22, 2004.




This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
M. C. Solaz-Fuster, J. V. Gimeno-Alcaniz, S. Ros, M. E. Fernandez-Sanchez, B. Garcia-Fojeda, O. C. Garcia, D. Vilchez, J. Dominguez, M. Garcia-Rocha, M. Sanchez-Piris, et al.
Regulation of glycogen synthesis by the laforin-malin complex is modulated by the AMP-activated protein kinase pathway
Hum. Mol. Genet., March 1, 2008; 17(5): 667 - 678.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. A. Worby, M. S. Gentry, and J. E. Dixon
Malin Decreases Glycogen Accumulation by Promoting the Degradation of Protein Targeting to Glycogen (PTG)
J. Biol. Chem., February 15, 2008; 283(7): 4069 - 4076.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
J. Turnbull, S. Kumar, Z.-P. Ren, S. Muralitharan, T. Naranian, C. A. Ackerley, and B. A. Minassian
Lafora Progressive Myoclonus Epilepsy: Disease Course Homogeneity in a Genetic Isolate
J Child Neurol, February 1, 2008; 23(2): 240 - 242.
[Abstract] [PDF]

Home page
 NeurologyHome page
P. Gomez-Garre, E. Gutierrez-Delicado, C. Gomez-Abad, J. Morales-Corraliza, V. E. Villanueva, S. Rodriguez de Cordoba, J. Larrauri, M. Gutierrez, J. Berciano, and J. M. Serratosa
Hepatic disease as the first manifestation of progressive myoclonus epilepsy of Lafora
Neurology, April 24, 2007; 68(17): 1369 - 1373.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
H. Lohi, J. Turnbull, X. C. Zhao, S. Pullenayegum, L. Ianzano, M. Yahyaoui, M. A. Mikati, N. P. Quinn, S. Franceschetti, F. Zara, et al.
Genetic diagnosis in Lafora disease: Genotype-phenotype correlations and diagnostic pitfalls
Neurology, March 27, 2007; 68(13): 996 - 1001.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
S Singh, I Sethi, S Francheschetti, C Riggio, G Avanzini, K Yamakawa, A V Delgado-Escueta, and S Ganesh
Novel NHLRC1 mutations and genotype-phenotype correlations in patients with Lafora's progressive myoclonic epilepsy.
J. Med. Genet., September 1, 2006; 43(9): e48 - e48.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.